F.L. Putnam Investment Management’s Lineage Cell Therapeutics LCTX Stock Holding History

F.L. Putnam Investment Management’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$399K	Buy	+304,562	New	+$421K	﹤0.01%	507

Other funds holding LCTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCWM

Red Crane Wealth Management San Francisco, California $136M AUM 18.56% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

WJWM

Williams Jones Wealth Management New York $8.86B AUM 22.16% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

F.L. Putnam Investment Management's LCTX Position: Q2 2026 in Review

F.L. Putnam Investment Management opened a new position in Lineage Cell Therapeutics (LCTX) in Q2 2026: 304,562 shares worth $399K. The stake represents ﹤0.01% of the portfolio and ranks #507 among its holdings.

58 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

F.L. Putnam Investment Management held 304,562 shares of Lineage Cell Therapeutics worth $399K as of Q2 2026.
Lineage Cell Therapeutics was a new F.L. Putnam Investment Management position in Q2 2026.
Lineage Cell Therapeutics made up ﹤0.01% of F.L. Putnam Investment Management's portfolio in Q2 2026, its #507 holding.
58 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on F.L. Putnam Investment Management's 13F filing for Q2 2026, filed 6 Aug 2026.